Adaptation of African Swine Virus in Non-Swine Cell Lines: A Preliminary Study for Vaccine Candidate
Authors:
- I Wayan Masa TenayaITI Wayan Masa Tenaya
- Kadek Karang AgustinaKAKadek Karang Agustina
- I Ketut SuadaISI Ketut Suada
- Ida Ayu Pasti ApsariIAIda Ayu Pasti Apsari
- Tri Komala SariTSTri Komala Sari
- Ni Made HandayaniNHNi Made Handayani
- Anak Agung Ayu Sauca Sunia WidayantariAWAnak Agung Ayu Sauca Sunia Widayantari
- Anak Agung Komang SuardanaASAnak Agung Komang Suardana
- I Made SumaryaISI Made Sumarya
- I Nyoman ArsanaIAI Nyoman Arsana
- I Putu SudiartawanISI Putu Sudiartawan
- I Wayan WahyudiI Wayan Wahyudi
Open Access
- 1 April 2025
- journal article
- Published by Universitas Airlangga in Jurnal Medik Veteriner
- Vol. 8 (1) , 114-123
Abstract
African Swine Fever (ASF) is among the most detrimental infectious viral diseases in pigs causing approximately 100% mortality. The disease was first reported about 83 years ago in Africa before spreading to Europe in 1957 and Asia in 2010. An adequate vaccine generally containing live attenuated virus isolates prepared in swine macrophages to control the disease is currently unavailable. Therefore, this study aimed to use murine neuroblastoma (N2a) cells, non-swine cell lines, to adapt African swine fever virus (ASFV) isolates for vaccine preparation. ASFV isolate called BL21 obtained from Bali and East Nusa Tenggara was previously propagated in swine macrophages. However, virus was currently adapted in the N2a cells to avoid unwanted issues associated with using swine macrophages, including microbial contamination, as well as technically laborious and ethical issues. The adapted BL21 was re-confirmed with quantitative polymerase chain reaction (q-PCR) and tested in vivo to examine the pathogenicity properties. The results showed that BL21 produced consistently and specifically positive q-PCR, killing experimental pigs with typical gross pathological changes of ASF. BL21 at a 10-3/mL dilution adapted in N2a cells showed similar antigenic properties causing the death of nearly 50% N2a cells in vitro and terminating all in vivo experimental pigs. In conclusion, the BL21 isolate reported in this study could be used as a vaccine candidate after more attenuation and particularly to determine a lethal dose of 50% (LD50) for future investigations.Keywords
This publication has 22 references indexed in Scilit:
- African swine fever virus – variants on the riseEmerging Microbes & Infections, 2022
- Evaluation of an I177L gene-based five-gene-deleted African swine fever virus as a live attenuated vaccine in pigsEmerging Microbes & Infections, 2022
- A Cell Culture-Adapted Vaccine Virus against the Current African Swine Fever Virus Pandemic StrainJournal of Virology, 2021
- African swine fever in North Sumatra and West Java provinces in 2019 and 2020, IndonesiaTransboundary and Emerging Diseases, 2021
- African swine fever – A review of current knowledgeVirus Research, 2020
- Flow cytometric analysis of lymphocyte subset kinetics in Bali cattle experimentally infected with Jembrana disease virusVeterinary Immunology and Immunopathology, 2012
- In vivo infection of IgG-containing cells by Jembrana disease virus during acute infectionVirology, 2009
- Development of a TaqMan® PCR assay with internal amplification control for the detection of African swine fever virusJournal of Virological Methods, 2003
- Reduction of CD4+ and CD8+ T lymphocytes during febrile periods in horses experimentally infected with equine infectious anemia virusVeterinary Immunology and Immunopathology, 1999
- On A Form of Swine Fever Occurring in British East Africa (Kenya Colony)Journal of Comparative Pathology and Therapeutics, 1921